Breaking News Instant updates and real-time market news.

NVRO

Nevro

$45.65

-2 (-4.20%)

08:28
11/06/18
11/06
08:28
11/06/18
08:28

Nevro price target lowered to $50 from $62 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered his price target for Nevro to $50 from $62 following quarterly results. While Q3 results were "solid," Q4 outlook and market commentary disappointed, he contends. The analyst reiterates a Market Perform rating on the shares.

NVRO Nevro
$45.65

-2 (-4.20%)

07/25/18
LEER
07/25/18
NO CHANGE
Target $90
LEER
Outperform
Nevro selloff overdone, says Leerink
Leerink analyst Danielle Antalffy is defending Nevro (NVRO) shares after a 26% selloff in response to a summary judgment ruling in which either the company's patents were ruled invalid or Boston Scientific (BSX) was ruled to not infringe. The analyst believes that even in a worst-case scenario, namely one in which Nevro's patents are invalidated, allowing other manufacturers to pursue high frequency therapy, the company would still be able to grow sales by about 5% in 2019. Antalffy reiterates an Outperform rating and $90 price target on Nevro's shares as she continues to believe the company's fundamentals remain relatively strong, particularly given where the stock is currently trading.
07/25/18
WBLR
07/25/18
NO CHANGE
WBLR
Outperform
Nevro patent ruling not as bad as it seems, says William Blair
William Blair analyst Margaret Kaczor says the summary judgement issued yesterday is not as bad as it seems for Nevro (NVRO). While the initial headline appears negative, the ruling is similar to the preliminary judgment published earlier this month, Kaczor tells investors in a research note. Though some of the claims in the patents have been invalidated, the remaining claims, which include frequency ranges of 1.5 kHz to 100 kHz, were not invalidated, the analyst adds. She points out, though, that the judge found Boston Scientific (BSX) did not infringe on the claims as its commercially available devices could not be programmed to frequencies that would infringe and that devices that could be programmed to high frequency that are being used in clinical trials are included in safe harbor provisions. This leaves the door open in the event that Boston commercially launches a device within the frequency ranges referenced above, Kaczor writes. She believes, however, that even if Boston moves to launch a high frequency device in the United States, the company would likely have to file for FDA approval following the completion of its high-frequency trial. Despite some level of uncertainty this ruling may bring, Nevro's risk/reward is favorable, Kaczor contends. She keeps an Outperform rating on the shares.
10/19/18
GSCO
10/19/18
DOWNGRADE
Target $44
GSCO
Sell
Nevro downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Isaac Ro downgraded Nevro (NRVO) to Sell and lowered his price target for the shares to $44 from $60. The company's cycle of negative estimate revisions is not yet over, Ro tells investors in a research note where he also upgraded DexCom (DXCM) to Neutral. The analyst thinks consensus revenue expectations for Nevro are still too high amid "ramping" competition, the company's ongoing patent litigation with Boston Scientific (BSX) and the hiring disruption in its sales force.
11/06/18
JPMS
11/06/18
DOWNGRADE
Target $45
JPMS
Neutral
Nevro downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Robbie Marcus downgraded Nevro to Neutral and lowered his price target for the shares to $45 from $77. Nevro posted Q3 results that beat conservative expectations, but "this was more than offset by first-time color on 2019 growth that came in well below consensus," Marcus tells investors in a post-earnings research note. The analyst believes Street numbers for 2019 revenue growth need to come down to the high-single-digit range from low-double-digits currently, and he wouldn't be surprised to see out-year expectations lowered to a similar range given the commentary. Marcus still believes Nevro's longer term outlook is attractive, but is stepping to the sidelines "with growth looking to slow meaningfully for at least the next few quarters."

TODAY'S FREE FLY STORIES

NCS

NCI Building

$7.66

-0.11 (-1.42%)

07:57
02/19/19
02/19
07:57
02/19/19
07:57
Downgrade
NCI Building rating change  »

NCI Building downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$21.79

-0.22 (-1.00%)

07:57
02/19/19
02/19
07:57
02/19/19
07:57
Hot Stocks
iQIYI obtains exclusive rights in China for the airing of "Catch-22" »

iQIYI announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TGLS

Tecnoglass

$8.45

0.145 (1.75%)

07:57
02/19/19
02/19
07:57
02/19/19
07:57
Conference/Events
Tecnoglass management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 07

    Mar

STIM

Neuronetics

$18.01

0.59 (3.39%)

07:55
02/19/19
02/19
07:55
02/19/19
07:55
Conference/Events
Neuronetics management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

CTL

CenturyLink

$13.73

0.96 (7.52%)

07:54
02/19/19
02/19
07:54
02/19/19
07:54
Upgrade
CenturyLink rating change  »

CenturyLink upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

ORPN

Bio Blast Pharma

$1.19

0.05 (4.39%)

, SEEL

Seelos Therapeutics

$3.64

-0.27 (-6.91%)

07:52
02/19/19
02/19
07:52
02/19/19
07:52
Hot Stocks
Bio Blast Pharma announces sale of Trehalose clinical development programs »

Bioblast Pharma (ORPN)…

ORPN

Bio Blast Pharma

$1.19

0.05 (4.39%)

SEEL

Seelos Therapeutics

$3.64

-0.27 (-6.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDVKY

Sandvik AB

$0.00

(0.00%)

07:52
02/19/19
02/19
07:52
02/19/19
07:52
Conference/Events
Sandvik AB management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 23

    May

NCS

NCI Building

$7.66

-0.11 (-1.42%)

07:50
02/19/19
02/19
07:50
02/19/19
07:50
Downgrade
NCI Building rating change  »

NCI Building downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$100.00

1.52 (1.54%)

07:49
02/19/19
02/19
07:49
02/19/19
07:49
Hot Stocks
Walmart raises annual dividend to $2.12 per share from $2.08 per share »

The board of Walmart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 03

    Mar

  • 06

    Mar

PRU

Prudential

$93.16

2.49 (2.75%)

07:48
02/19/19
02/19
07:48
02/19/19
07:48
Conference/Events
Prudential management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 05

    Jun

NSC

Norfolk Southern

$182.88

1.05 (0.58%)

07:48
02/19/19
02/19
07:48
02/19/19
07:48
Downgrade
Norfolk Southern rating change  »

Norfolk Southern cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

UNIT

Uniti Group

$20.00

0.53 (2.72%)

, WIN

Windstream

$3.37

0.2 (6.31%)

07:46
02/19/19
02/19
07:46
02/19/19
07:46
Downgrade
Uniti Group, Windstream rating change  »

Uniti Group downgraded to…

UNIT

Uniti Group

$20.00

0.53 (2.72%)

WIN

Windstream

$3.37

0.2 (6.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

  • 11

    Mar

BBD

Banco Bradesco

$12.40

0.07 (0.57%)

07:46
02/19/19
02/19
07:46
02/19/19
07:46
Conference/Events
Banco Bradesco management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

PCG

PG&E

$15.50

0.02 (0.13%)

07:46
02/19/19
02/19
07:46
02/19/19
07:46
Upgrade
PG&E rating change  »

PG&E upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:45
02/19/19
02/19
07:45
02/19/19
07:45
Hot Stocks
Breaking Hot Stocks news story on Noble Midstream »

Noble Midstream sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

07:45
02/19/19
02/19
07:45
02/19/19
07:45
General news
Global Risks Ebb and Flow: »

Global Risks Ebb and…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:44
02/19/19
02/19
07:44
02/19/19
07:44
Recommendations
XPO Logistics analyst commentary  »

XPO Logistics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:43
02/19/19
02/19
07:43
02/19/19
07:43
Hot Stocks
Noble Midstream sees FY19 capital budget $335M-$375M »

Noble Midstream's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:42
02/19/19
02/19
07:42
02/19/19
07:42
Hot Stocks
Noble Midstream sees adjusted EBITDA from partnership of at least $300M in 2020 »

Anticipates adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CSX

CSX

$72.52

0.91 (1.27%)

07:41
02/19/19
02/19
07:41
02/19/19
07:41
Downgrade
CSX rating change  »

CSX downgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    May

HEXO

HEXO Corp

$5.57

0.17 (3.15%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Initiation
HEXO Corp initiated  »

HEXO Corp initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Downgrade
Windstream rating change  »

Windstream downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

AMSC

AMSC

$15.00

-0.8 (-5.06%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Conference/Events
AMSC management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Hot Stocks
Noble Midstream sees FY19 adjusted EBITDA $340M-$390M »

"Entering 2019, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

07:40
02/19/19
02/19
07:40
02/19/19
07:40
General news
Treasury Market Outlook: bond yields have dipped slightly lower amid risk-off flows »

Treasury Market Outlook:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.